Drug eluting coronary stents coated with a bioactive and biostable polymer system (THBA70), based on acrylate copolymers bearing a salicylic acid derivative as side substituent, were evaluated. The microstructural architecture of the copolymer THBA70 comprises a random copolymer of a methacrylate derivative from triflusal (4-trifluoromethyl salicylic acid) with 45 mol% of THEMA (2-methacryloyloxyethyl [2-(acetyloxy)-4-(trifluoromethyl)] benzoate), which makes the system anti-thrombogenic with good adhesion to the surface of metallic stents. The bioactive coating prevented thrombosis, an adverse effect associated with the implantation of drug-eluting stents. The in vitro drug delivery of drug-eluting stents under dynamic conditions indicated excellent controlled drug release. The THBA70 films loaded with relatively low concentrations of taxol or simvastatin in contact with fibroblasts produced inhibition of cell proliferation with a dose-dependent bioactivity.
TsuchidaPWSBruiningNDudekD. Two-year serial coronary angiographic and intravascular ultrasound analysis of in-stent angiographic late lumen loss and ultrasonic neointimal volume from the TAXUS II trial. Am J Cardiol2007; 99: 607–615.
2.
GargSSerruysPW. Coronary stents: current status. J Am Coll Cardiol2010; 56: S1–S42.
3.
SharkawiTLeyni-BarbazDChikhN. Evaluation of the in vitro drug release from resorbable biocompatible coatings for vascular stents. J Bioact Compat Pol2005; 20: 153–168.
4.
ShinHSParkKJi HeungK. Biocompatible PEG grafting on DLC-coated nitinol alloy for vascular stents. J Bioact Compat Pol2009; 24: 316–328.
5.
HolmesDRTeirsteinPSatlerL. Sirolimus-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the SISR randomized trial. J Amer Med Assoc2006; 295: 1264–1273.
6.
StoneGWEllisSGO’ShaughnessyCD. Paclitaxel-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the TAXUS V ISR randomized trial. J Amer Med Assoc2006; 295: 1253–1263.
7.
ByrneRASarafoffNKastratiA. Drug-eluting stents in percutaneous coronary intervention: a benefit-risk assessment. Drug Saf2009; 32: 749–770.
8.
CihanSOnumaYMagroM. Four-year clinical outcome of sirolimus- and paclitaxel-eluting stents compared to bare-metal stents for the percutaneous treatment of stable coronary artery disease. Catheter Cardiovasc Interv2010; 76: 41–49.
9.
KastratiADibraASpauldingC. Meta-analysis of randomized trials on drug-eluting stents vs. bare-metal stents in patients with acute myocardial infarction. Eur Heart J2007; 28: 2706–2713.
10.
WesselyR. New drug-eluting stent concepts. Nat Rev Cardiol2010; 7: 194–203.
11.
GagliardiMSilvestriDCristalliniC. Combined drug release from biodegradable bilayer coating for endovascular stents. J Biomed Mater Res B Appl Biomater2010; 93: 375–385.
12.
WangZXHongBFXuZ. New biodegradable drug-eluting stents for urethral strictures in a rabbit model. J Bioact Compat Pol2011; 26: 89–98.
MartinDMBoyleFJ. Drug-eluting stents for coronary artery disease: a review. Med Eng Phys2011; 33: 148–163.
15.
CamenzindEStegPGWijnsW. Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern. Circulation2007; 115: 1440–1455.
16.
HuangYVenkatramanSSBoeyFYC. The short-term effect on restenosis and thrombosis of a cobalt-chromium stent eluting two drugs in a porcine coronary artery model: new technologies. J Interv Cardiol2009; 22: 466–478.
17.
HuangYVenkatramanSSBoeyFYC. In vitro and in vivo performance of a dual drug-eluting stent (DDES). Biomaterials2010; 31: 4382–4391.
18.
RodriguezGFernandez-GutierrezMParraJ. Bioactive polymeric systems with platelet antiaggregating activity for the coating of vascular devices. Biomacromolecules2010; 11: 2740–2747.
LeeTSChangCCZhuY. Simvastatin induces heme oxygenase-1: a novel mechanism of vessel protection. Circulation2004; 110: 1296–1302.
21.
IndolfiCCioppaAStabileE. Effects of hydroxymethylglutaryl coenzyme A reductase inhibitor simvastatin on smooth muscle cell proliferation in vitro and neointimal formation in vivo after vascular injury. J Am Coll Cardiol2000; 35: 214–221.
22.
GrubeESilberSHauptmannKE. Six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation2003; 107: 38–42.
23.
RodríguezGGallardoASan RománJ. New resorbable polymeric systems with antithrombogenic activity. J Mater Sci Mater Med1999; 10: 873–878.
24.
MosmannT. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods1983; 65: 55–63.
25.
LennernasHFagerG. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. similarities and differences. Clin Pharmacokinet1997; 32: 403–425.
26.
PorterKETurnerNAO’ReganDJ. Simvastatin reduces human atrial myofibroblast proliferation independently of cholesterol lowering via inhibition of RhoA. Cardiovas Res2004; 61: 745–755.
27.
WolfgangE. Statin-induced vascular smooth muscle cell apoptosis: a possible role in the prevention of restenosis?Curr Drug Targets Cardiovasc Haematol Disord2005; 5: 135–144.
28.
ChenZFukutomiTZagoAC. Simvastatin reduces neointimal thickening in low-density lipoprotein receptor-deficient mice after experimental angioplasty without changing plasma lipids. Circulation2002; 106: 20–23.
29.
ReljaBMederFWilhelmK. Simvastatin inhibits cell growth and induces apoptosis and G0/G1 cell cycle arrest in hepatic cancer cells. Int J Mol Med2010; 26: 735–741.
30.
Taraseviciene-StewartLScerbaviciusRChoeKH. Simvastatin causes endothelial cell apoptosis and attenuates severe pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol2006; 291: 668–676.
